Techne Corp. (NASDAQ:TECH)’s share price was down 2% during trading on Thursday . The stock traded as low as $112.00 and last traded at $112.02, with a volume of 104,049 shares trading hands. The stock had previously closed at $114.33.

Several equities analysts have recently commented on TECH shares. Janney Montgomery Scott raised shares of Techne Corp. from a “neutral” rating to a “buy” rating and upped their price objective for the company from $100.00 to $118.00 in a research note on Tuesday, May 3rd. Zacks Investment Research raised shares of Techne Corp. from a “hold” rating to a “buy” rating and set a $113.00 price objective for the company in a research note on Saturday, May 7th. Finally, Leerink Swann reaffirmed a “hold” rating on shares of Techne Corp. in a research note on Sunday, July 10th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $112.60.

The company has a market cap of $4.13 billion and a P/E ratio of 39.47. The stock’s 50-day moving average is $112.08 and its 200 day moving average is $96.72.

Techne Corp. (NASDAQ:TECH) last posted its earnings results on Tuesday, May 3rd. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.89 by $0.12. The company had revenue of $131 million for the quarter, compared to analysts’ expectations of $122.65 million. The business’s revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.88 earnings per share. On average, equities analysts forecast that Techne Corp. will post $3.64 EPS for the current fiscal year.

In related news, Director Charles A. Dinarello sold 5,000 shares of the firm’s stock in a transaction on Monday, May 9th. The shares were sold at an average price of $101.91, for a total transaction of $509,550.00. Following the completion of the transaction, the director now directly owns 6,559 shares of the company’s stock, valued at $668,427.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Roger C. Lucas sold 500 shares of the firm’s stock in a transaction on Friday, May 6th. The shares were sold at an average price of $100.24, for a total transaction of $50,120.00. Following the transaction, the director now directly owns 3,915 shares of the company’s stock, valued at $392,439.60. The disclosure for this sale can be found here.

Several institutional investors have modified their holdings of TECH. Royce & Associates LLC boosted its position in shares of Techne Corp. by 11.2% in the fourth quarter. Royce & Associates LLC now owns 908,569 shares of the company’s stock worth $81,771,000 after buying an additional 91,790 shares during the last quarter. TD Asset Management Inc. boosted its position in shares of Techne Corp. by 306.9% in the fourth quarter. TD Asset Management Inc. now owns 29,300 shares of the company’s stock worth $2,637,000 after buying an additional 22,100 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Techne Corp. by 13.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 155,643 shares of the company’s stock worth $14,009,000 after buying an additional 18,374 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of Techne Corp. by 40.1% in the fourth quarter. GSA Capital Partners LLP now owns 39,841 shares of the company’s stock worth $3,586,000 after buying an additional 11,409 shares during the last quarter. Finally, BHF Kleinwort Benson Group S.A. boosted its position in shares of Techne Corp. by 65.8% in the fourth quarter. BHF Kleinwort Benson Group S.A. now owns 22,995 shares of the company’s stock worth $2,070,000 after buying an additional 9,130 shares during the last quarter.

Bio-Techne Corporation (Bio-Techne), formerly Techne Corporation, develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology, Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products around the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.